Clinical trial / 2014
Trans-resveratrol supplementation promoted foot ulcer size reduction and decreased plasma fibrinogen in patients with type 2 diabetes.
A randomized pilot trial evaluated 50 mg of trans-resveratrol (t-RSV) or placebo twice daily for 60 days in 24 patients with type 2 diabetes and newly diagnosed diabetic foot ulcers. Reduction in parameters reflecting ulcer size was more profound in the RSV group compared to placebo, and RSV-treated patients showed marginally improved foot pressure test performance. A statistically significant decline in plasma fibrinogen, but not CRP, occurred with RSV treatment. Improvements in lipid profiles and fasting glucose occurred in both groups and were not related to RSV.
- Study type
- Placebo-controlled, examiner-blinded, parallel-group randomized pilot trial
- Who was studied
- 24 type 2 diabetes patients with diabetic foot syndrome (15 males, 9 females, average age 56.4 ± 9.1 years)
- What was measured
- Diabetic ulcer size, foot pressure test, plasma fibrinogen, CRP, lipid profile, and fasting glucose
THE PAPER
Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients.
Bashmakov YK, Assaad-Khalil SH, Abou Seif M, Udumyan R, Megallaa M, Rohoma KH, Zeitoun M, Petyaev IM. ISRN Endocrinol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.